Ketamine Plus Lithium in Treatment-Resistant Depression
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the antidepressant effect of ketamine when given
repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention
strategy for patients with treatment-resistant depression (TRD) who respond to an initial
series of ketamine infusions. Ketamine is a Food and Drug Administration approved anesthetic
(a drug used to produce loss of consciousness before and during surgery). Ketamine is not
approved for the treatment of major depressive disorder and is considered experimental in
this study. An additional purpose of this study is to research the effects of ketamine on
brain function.
You may qualify to take part in this research study because you have been diagnosed with
major depressive disorder (MDD) and have not responded to past treatments.